Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Clinical trial NCT01909453 · COMPLETED
Trial details
- NCT number
- NCT01909453
- Sponsor
- Pfizer
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-09-12
- Primary completion
- 2016-11-09
- Enrollment
- 921
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.